NIH/National Institute of Allergy and Infectious Diseases

Diseases, Conditions, Syndromes

Experimental NIH Sudan virus vaccine protects macaques

A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. ...

Diseases, Conditions, Syndromes

Marburg virus vaccine shows promising results in first-in-human study

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers ...

Medical research

Probiotic markedly reduces S. Aureus colonization in phase 2 trial

A promising approach to control Staphylococcus aureus bacterial colonization in people—using a probiotic instead of antibiotics—was safe and highly effective in a Phase 2 clinical trial. The new study, reported in The ...

Medical research

Developing mucosal vaccines for respiratory viruses

Vaccines that provide long-lasting protection against influenza, coronaviruses and respiratory syncytial virus (RSV) have proved exceptionally difficult to develop. In a new review article in Cell Host & Microbe, researchers ...

Oncology & Cancer

Experimental cancer vaccine shows promise in animal studies

An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious ...

Diseases, Conditions, Syndromes

Monoclonal antibody prevents malaria infection in African adults

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody ...

page 3 from 40